Sartorius's Shares Drop on Outlook Cut, Preliminary 3Q Declines
n
By Andrea Figueras
Shares in Sartorius tumbled Friday after the company downgraded its full-year targets and posted lower preliminary sales and earnings for the first nine months of 2023.
At 0754 GMT, Sartorius's shares were down 12% to EUR282.20, while shares in its Sartorius Stedim Biotech subsidiary also traded lower at 13%.
The German life-sciences group now expects sales to fall around 17%, while it previously saw a decline in the low to mid-teens percentage range, and estimates the underlying earnings before interest, taxes, depreciation and amortization margin slightly above 28%, down from a prior forecast around 30%, it said. The company also said its mid-term guidance is under review.
Sartorius did little to improve a weak investor sentiment ahead of its third-quarter results, although the outlook cut was broadly in line with expectations, Citi analyst Vineet Agrawal said in a research note.
The stock is likely to be volatile until trends stabilize and there is more clarity, though the mid-and-long term growth trends of the industry remain intact, Jefferies analyst James Vane-Tempest wrote in a research note.
Consolidated revenue for the first nine months of the year fell around 16% to 2.5 million euros ($2.6 million) in constant currencies and the underlying Ebitda dropped to EUR733 million from EUR1.05 billion last year, Sartorius said.
While the decline in the bioprocess-solutions division seems to be bottoming out, the magnitude of the miss in the lab-products-and-services segment was probably larger than expected, Citi said.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
October 13, 2023 04:23 ET (08:23 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth